Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study.

导出 OA

翻译打印收藏纠错

作者： François,Curtin ^[1] ; Virginie,Vidal ^[2] ; Corinne,Bernard ^[1] ; Arno,Kromminga ^[1] ; Alois B,Lang ^[3] ; Hervé,Porchet ^[1]

作者单位： a GeNeuro SA, Chemin des Aulx 18 , Plan-les-Ouates/Geneva , Switzerland. ^[1] b Division of Clinical Pharmacology and Toxicology, Rue Perret-Gentil, University of Geneva , Geneva , Switzerland. ^[2] c IPM Biotech GmbH , Lademannbogen 61, Hamburg , Germany. ^[3] d Department of Pharmacology , University of Pretoria , Pretoria , South Africa. ^[4]

关键词 Cerebrospinal fluid clinical trial monoclonal antibody multiple sclerosis pharmacokinetics safety

主题词成年人(Adult);剂量效应关系, 药物(Dose-Response Relationship, Drug);人类(Humans);男(雄)性(Male);中年人(Middle Aged);多发性硬化(Multiple Sclerosis);青年人(Young Adult)

DOI 10.1080/19420862.2016.1168956

PMID 27030142

发布时间 2022-04-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交